Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Pertussis: later-stage trial registry
A small indexed set (15 trials) with no open enrollment listed right now.
Corpus placement: #1,140 of 28,707 conditions by registered trial count.
15 US clinical trials · none currently recruiting · #1,140 of 28,707 conditions by registered trial count
Pertussis: 15 US clinical trials tracked, none currently recruiting.
Pertussis is the subject of 15 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 7 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Sanofi Pasteur, a Sanofi Company, running 6 of these trials.
Enrollment posture brief
Registry condition pertussis
OPEN 0 | RECR 0% | LATE 7 | EARLY 4 | RANK #1140 | SPON 6
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Pertussis has no open enrollment in this registry pull (15 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Pertussis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Pertussis is recruiting below its size-band peers.
0 of 15 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Pertussis research.
Sanofi Pasteur, a Sanofi Company accounts for 6 of 15 trials (40%). 5 distinct sponsors appear on at least one study for this condition label.
-
Typical Pertussis enrolment sits around 647 participants.
Median target enrolment is 647 among the 15 trials that report a genuine target (sentinel values excluded). 3 of those (20%) plan for fewer than 100 participants.
-
Pertussis research is mostly interventional.
13 interventional and 2 observational studies make up this index (86.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Indexed trials (enrollment closed)
15 total, page 1 of 1
Descriptive, Post-marketing, Passive Surveillance Safety Study of ADACEL™ Vaccine
Sanofi Pasteur, a Sanofi Company
NCT00258882
How Does the Clinical Tool 'What's Going Around' Affect Clinical Practice
Endeavor Health
NCT01979588
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
Sanofi Pasteur, a Sanofi Company
NCT01346293
Boostrix® Pregnancy Registry
GlaxoSmithKline
NCT02096276
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
Sanofi Pasteur, a Sanofi Company
NCT01659996
Study of Adacel® Vaccine Administered to Persons 10 Years of Age
Sanofi
NCT01311557
Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™
Sanofi Pasteur, a Sanofi Company
NCT00802867
Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX®
Sanofi
NCT00319553
Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® Vaccine
Sanofi Pasteur, a Sanofi Company
NCT00347958
Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents
Sanofi Pasteur, a Sanofi Company
NCT01629589
Study on the Safety and Immunogenicity of Boostrix Vaccine in Pregnant Malian Women and Their Infants
National Institute of Allergy and Infectious Diseases (NIAID)
NCT03589768
Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00013871
Pertussis Vaccine in Healthy Pregnant Women
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00707148
Safety and Immunogenicity of Intranasal BPZE1 Vaccination in Healthy Adults
National Institute of Allergy and Infectious Diseases (NIAID)
NCT03541499
Pentavalent DTaP-Hep B-IPV
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00133445
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 3 |
| Phase 3 | 1 |
| Phase 4 | 6 |
Top Sponsors
Named interventions
Most-linked intervention names on Pertussis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Pertussis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Pertussis page
15 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Pertussis trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Sanofi Pasteur, a Sanofi Company sponsors the most Pertussis trials on record, review their full trial history before evaluating a specific study. See Sanofi Pasteur, a Sanofi Company's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Pertussis condition card totals 15 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.